Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups
Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.
- UK: Views Needed on Novel Food Applications
The agency is seeking comments regarding D-tagatose and Noni juice.
- UK: Views Needed on Novel Food Applications
The agency is seeking comments regarding D-tagatose and Noni juice.
- UK: Views Needed on Novel Food Applications
The agency is seeking comments regarding D-tagatose and Noni juice.
- UK: Views Needed on Novel Food Applications
The agency is seeking comments regarding D-tagatose and Noni juice.
- Australia Raises Regulatory Bar on Herbal Products
Australian government has announced that the Therapeutic Goods Administration (TGA) will demand a “much more rigorous assessment” of all herbal and homeopathic ingredients used in complementary medicines.
- Australia Raises Regulatory Bar on Herbal Products
Australian government has announced that the Therapeutic Goods Administration (TGA) will demand a “much more rigorous assessment” of all herbal and homeopathic ingredients used in complementary medicines.
- Australia Raises Regulatory Bar on Herbal Products
Australian government has announced that the Therapeutic Goods Administration (TGA) will demand a “much more rigorous assessment” of all herbal and homeopathic ingredients used in complementary medicines.
- Australia Raises Regulatory Bar on Herbal Products
Australian government has announced that the Therapeutic Goods Administration (TGA) will demand a “much more rigorous assessment” of all herbal and homeopathic ingredients used in complementary medicines.
- Australia Raises Regulatory Bar on Herbal Products
Australian government has announced that the Therapeutic Goods Administration (TGA) will demand a “much more rigorous assessment” of all herbal and homeopathic ingredients used in complementary medicines.
- Confirmation Hearings Set for Lester Crawford
Lester Crawford will go before the Senate Health, Education, Labor and Pensions Committee on Thursday, March 17, in a confirmation hearing on his nomination to be FDA Commissioner.
- Confirmation Hearings Set for Lester Crawford
Lester Crawford will go before the Senate Health, Education, Labor and Pensions Committee on Thursday, March 17, in a confirmation hearing on his nomination to be FDA Commissioner.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- U.K. Food Standards Agency Approves Continued Sale of Chromax® Chromium Picolinate
Company announces filing of dossier for European-wide approval of Chromax; UK Food Standards Agency has granted 'derogation' for Chromax® chromium picolinate in England, Scotland, Wales and Northern Ireland.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- NSF International and American Herbal Pharmacopoeia®
Strategic Partnership Raises the Bar on Botanical Industry Standards. NSF International (NSF), an independent, not-for-profit organization, announced a new strategic partnership with American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization.
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Appointment of New Food Standards Agency (UK) Chair
Dame Deirdre Hutton - currently Deputy Chair of the Financial Services Authority, a member of the Better Regulation Task Force, Chair of the National Consumer Council and Deputy Chair of the European Food Safety Authority - has been appointed Chair of the Food Standards Agency (FSA).
- Diet Patch Sellers Settle Can-Spam Charges
Operators who sent millions of illegal e-mail messages to market their bogus diet patch have settled Federal Trade Commission charges that their operation violated federal laws, including the CAN-SPAM Act.
- Diet Patch Sellers Settle Can-Spam Charges
Operators who sent millions of illegal e-mail messages to market their bogus diet patch have settled Federal Trade Commission charges that their operation violated federal laws, including the CAN-SPAM Act.
- Virgo Announces Details for SupplySide East FDA and Industry Panel on New Dietary Ingredients
Session scheduled for Friday, May 6, from 2:15 to 3:45 p.m will focus on New Dietary Ingredients (NDIs), and FDA speakers will be joined by representatives from the American Herbal Products Association (AHPA) and Ullman, Shapiro & Ullman.
- Virgo Announces Details for SupplySide East FDA and Industry Panel on New Dietary Ingredients
Session scheduled for Friday, May 6, from 2:15 to 3:45 p.m will focus on New Dietary Ingredients (NDIs), and FDA speakers will be joined by representatives from the American Herbal Products Association (AHPA) and Ullman, Shapiro & Ullman.
- Virgo Announces Details for SupplySide East FDA and Industry Panel on New Dietary Ingredients
Session scheduled for Friday, May 6, from 2:15 to 3:45 p.m will focus on New Dietary Ingredients (NDIs), and FDA speakers will be joined by representatives from the American Herbal Products Association (AHPA) and Ullman, Shapiro & Ullman.
- Virgo Announces Details for SupplySide East FDA and Industry Panel on New Dietary Ingredients
Session scheduled for Friday, May 6, from 2:15 to 3:45 p.m will focus on New Dietary Ingredients (NDIs), and FDA speakers will be joined by representatives from the American Herbal Products Association (AHPA) and Ullman, Shapiro & Ullman.
- Facts about Codex and Dietary Supplements
Association presents document to address Codex, its backgground and effect.
- Facts about Codex and Dietary Supplements
Association presents document to address Codex, its backgground and effect.
- Facts about Codex and Dietary Supplements
Association presents document to address Codex, its backgground and effect.
- Facts about Codex and Dietary Supplements
Association presents document to address Codex, its backgground and effect.
- Court Rules in Favor of Nutraceutical Regarding Low Dose Ephedra Products
Court rules in favor of Nutraceutical against the FDA, noting that no evidence of low-dose risk (10mg per day or less of ephedrine alkaloids) had been presented by FDA, and that DSHEA contains no provisions for risk-benefit analysis.
- Court Rules in Favor of Nutraceutical Regarding Low Dose Ephedra Products
Court rules in favor of Nutraceutical against the FDA, noting that no evidence of low-dose risk (10mg per day or less of ephedrine alkaloids) had been presented by FDA, and that DSHEA contains no provisions for risk-benefit analysis.
- Court Rules in Favor of Nutraceutical Regarding Low Dose Ephedra Products
Court rules in favor of Nutraceutical against the FDA, noting that no evidence of low-dose risk (10mg per day or less of ephedrine alkaloids) had been presented by FDA, and that DSHEA contains no provisions for risk-benefit analysis.
- Court Rules in Favor of Nutraceutical Regarding Low Dose Ephedra Products
Court rules in favor of Nutraceutical against the FDA, noting that no evidence of low-dose risk (10mg per day or less of ephedrine alkaloids) had been presented by FDA, and that DSHEA contains no provisions for risk-benefit analysis.
- Court Rules in Favor of Nutraceutical Regarding Low Dose Ephedra Products
Court rules in favor of Nutraceutical against the FDA, noting that no evidence of low-dose risk (10mg per day or less of ephedrine alkaloids) had been presented by FDA, and that DSHEA contains no provisions for risk-benefit analysis.
- Court Overturns FDA Ban on Low-dose Ephedra Products
US District Court rules that FDA failed to prove that a dosage of 10 milligrams or less of ephedrine alkaloids presents an unreasonable risk of illness of injury; ruling has no effect on FDA’s ban on higher dose products, such as products that were formerly sold to promote weight loss.
- Court Overturns FDA Ban on Low-dose Ephedra Products
US District Court rules that FDA failed to prove that a dosage of 10 milligrams or less of ephedrine alkaloids presents an unreasonable risk of illness of injury; ruling has no effect on FDA’s ban on higher dose products, such as products that were formerly sold to promote weight loss.
- CRN Responds To Utah Court Ruling On Ephedra
Association notes that ruling "was the next step in a legal process that serves to protect consumers. Both companies and individuals have a right to challenge laws and regulations and it is reasonable to expect regulations to conform to statutory standards in order to withstand legal challenges." Association points out that ruling only applies to a very specific segemnt and is not a complete oveturning of the ban.
- CRN Responds To Utah Court Ruling On Ephedra
Association notes that ruling "was the next step in a legal process that serves to protect consumers. Both companies and individuals have a right to challenge laws and regulations and it is reasonable to expect regulations to conform to statutory standards in order to withstand legal challenges." Association points out that ruling only applies to a very specific segemnt and is not a complete oveturning of the ban.
- Court Rules in Favor of Supplement Company in Ephedra Suit
It appears that ephedra at low doses may reenter the market, subject to some risk
- Court Rules in Favor of Supplement Company in Ephedra Suit
It appears that ephedra at low doses may reenter the market, subject to some risk
- Court Rules in Favor of Supplement Company in Ephedra Suit
It appears that ephedra at low doses may reenter the market, subject to some risk
- Court Rules in Favor of Supplement Company in Ephedra Suit
It appears that ephedra at low doses may reenter the market, subject to some risk
- Court Rules in Favor of Supplement Company in Ephedra Suit
It appears that ephedra at low doses may reenter the market, subject to some risk
- Federal Court Overturns FDA Ban On Ephedrine-Containing Dietary Supplements
Law firm comments and provides analysis on court ruling.
- Federal Court Overturns FDA Ban On Ephedrine-Containing Dietary Supplements
Law firm comments and provides analysis on court ruling.
- Splenda to Face California Courts on 'False Advertising' Claims
Federal court in Los Angeles has ruled that the makers of the artificial chemical sweetener Splenda will face allegations that their marketing and advertising campaign is both false and misleading.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Burlington, Vermont - March 17, 2005 --The United States Attorney's Office for the District of Vermont, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) and Office of Research Integrity (ORI) announced today that Dr. Eric T. Poehlman, 49, a former tenured research professor at the University of Vermont (UVM) College of Medicine in Burlington, Vermont, has agreed to a comprehensive criminal, civil, and administrative settlement related to his scientific misconduct in falsifying and fabricating research data in numerous federal grant applications and in academic articles from 1992 to 2002.
According to court documents filed today, Dr. Poehlman has agreed to plead guilty to making material false statements in a research grant application in April 1999, upon which the National Institutes of Health (NIH) paid $542,000 for Dr. Poehlman's research activities. In addition, Dr. Poehlman has agreed to pay $180,000 to settle a civil complaint related to numerous false grant applications he filed while at UVM. In addition, Dr. Poehlman will pay $16,000 in attorney's fees to counsel for Walter F. DeNino, a research assistant whose complaint of scientific misconduct spurred an investigation by UVM. Also, Dr. Poehlman has agreed to be barred for life from seeking or receiving funding from any federal agency in the future, including all components of the Public Health Service, and to submit numerous letters of retraction and correction to scientific journals related to his scientific misconduct. Dr. Poehlman also agreed to be permanently excluded from participation in all Federal health care programs. In these agreements, Dr. Poehlman has admitted that he acted alone in falsifying and fabricating research data and filing false grant applications.
"Preserving the integrity of the grant process administered by the Public Health Service is a priority for the Department of Justice," said United States Attorney David V. Kirby. "This prosecution demonstrates that academic researchers will be held fully accountable for fraud and scientific misconduct. Dr. Poehlman fraudulently diverted millions of dollars from the Public Health Service to support his research projects. This in turn siphoned millions of dollars from the pool of resources available for valid scientific research proposals. As this prosecution proves, such conduct will not be tolerated."
Acting Assistant Secretary for Health, Cristina V. Beato, M.D., acknowledges the "invaluable assistance of the Department of Justice in bringing this case to a conclusion and upholding the high standards for research integrity in research supported by the Public Health Service." HHS actions against Dr. Poehlman include a life time debarment from receiving Public Health Service research funds and an agreement to retract or correct ten scientific articles due to research misconduct. Dr. Beato added that "while criminal charges against research scientists are rare, the egregiousness of Dr. Poehlman's conduct in this case fully supports the actions of the U.S. Attorney's Office and the administrative actions taken by HHS." Through ORI, HHS is authorized to investigate and oversee institutional investigations of allegations of research misconduct in order to protect the integrity of Public Health Service funded research.
Dr. Poehlman will appear for arraignment and to plead guilty to the criminal charge filed today at a date to be determined by the Court. Dr. Poehlman faces up to five years imprisonment on the criminal charge, but the United States has agreed to take no position on a request by Dr. Poehlman to receive a more lenient sentence based upon his cooperation with authorities and his acceptance of responsibility. The civil settlement agreement will become effective after approval by the Court. The administrative settlement will be effective immediately.
A. Dr. Poehlman's Research Activities and Scientific Misconduct
From 1987 to 2001, Dr. Poehlman held various research positions as an assistant, associate, and full professor of medicine at the UVM College of Medicine in Burlington, Vermont (1987-1993; 1996-2001), and the University of Maryland in Baltimore, Maryland (1993-1996). In these academic positions, Dr. Poehlman conducted research on human subjects related to exercise physiology and other topics that was funded primarily by grants from federal public health agencies and departments, including the NIH, the U.S. Department of Agriculture ("USDA"), and the Department of Defense.
From in or about 1992 to 2000, Dr. Poehlman submitted seventeen (17) research grant applications to federal agencies or departments that included false and fabricated research data. In these grant applications, Dr. Poehlman requested approximately $11.6 million in federal research funding. In most cases, Dr. Poehlman falsified and fabricated research data in the "preliminary studies" sections of grant applications in order to support the scientific basis for and his expertise in conducting the proposed research. Reviewers of these grant applications relied on the accuracy of the "preliminary studies" to determine if a grant should be recommended for award. While many of the grant applications were not awarded, NIH and USDA expended approximately $2.9 million in research funding based on grant applications with false and fabricated research data.
Dr. Poehlman falsified and fabricated research data in grant applications and research papers related to several topics including his study of the impact of the menopause transition on women's metabolism ("the Longitudinal Menopause Study"), his study of the impact of aging in older men and women on a wide range of physical and metabolic measures ("the Longitudinal Study of Aging"), and his proposal to study the impact of hormone replacement therapy ("HRT") on obesity in post-menopausal women ("the Prospective HRT Study"). Dr. Poehlman also presented falsified and fabricated data in grant applications and academic papers related to his study of metabolism in Alzheimer's patients and the effect of endurance training on metabolism.
B. The Longitudinal Menopause Study: 1994-2000
Beginning in 1994, Dr. Poehlman began presenting research data to academic colleagues that was purportedly from a study of women who were tested for basic metabolic characteristics before and after their transition through menopause. Dr. Poehlman presented the findings of the purported Longitudinal Menopause Study in an academic paper entitled "Changes in Energy Balance and Body Composition at Menopause: A Controlled Longitudinal Study," which was published by the Annals of Internal Medicine in 1995 ("the 1995 Annals Article"). The purported Longitudinal Menopause Study and the 1995 Annals Article were based almost entirely on falsified and fabricated research data. Dr. Poehlman represented in the 1995 Annals Article that he had tested 35 healthy women for basic metabolic characteristics and retested the same women six years later for the same characteristics. In fact, Dr. Poehlman falsified and fabricated test results for all but three of the 35 women in the study. From 1995 to 2000, Dr. Poehlman used the false and fabricated research data from the Longitudinal Menopause Study and the Annals Article in nine NIH grant applications, two USDA grant applications, and an additional six published academic papers, which were often cited in the grant applications.
C. The Longitudinal Study of Aging: 1996-2000
In 1996, Dr. Poehlman initiated a new project where he planned to recruit subjects who had previously been tested at UVM from 1987 to 1993 and retest them for the same and additional physical and metabolic characteristics over time. Beginning in 1999, Dr. Poehlman began presenting falsified and fabricated data from this Longitudinal Study on Aging to seek additional federally-funded grants for his research projects. In these grant applications, Dr. Poehlman exaggerated the number of subjects tested and changed the values for the physical characteristics of the subjects and the test results for these subjects (often reversing the values from the initial test and the retest) in order to create trends during the aging process that were not reflected in the actual research data. In 1999 and 2000, Dr. Poehlman presented the same or similar false research data in three grant applications to the NIH and to the USDA.
D. The Prospective Hormone Replacement Therapy ("HRT") Study: 1999-2000
Beginning in 1996, Dr. Poehlman was a co-investigator on a study at UVM designed to evaluate the effect of HRT on 20 post-menopausal women over several years time. Among other things, the study had double-blind controls so that the researchers and the patients were unaware of any test results (or even who received HRT or the placebo) until the study was completed in 2002. In 1999 and 2000, Dr. Poehlman used data purportedly from the Prospective HRT Study in two grant applications to NIH seeking federal funding for additional HRT studies. In fact, Dr. Poehlman did not have access to the data and just fabricated the preliminary test results in the grant applications.
E. UVM and Federal Investigations: 2000-2004
Beginning in December 2000 and continuing until April 2002, the UVM College of Medicine conducted an investigation of scientific misconduct by Dr. Poehlman while at UVM. The investigation began in response to allegations of scientific misconduct by Walter F. Denino, one of Poehlman's research assistants. During the course of this investigation, Dr. Poehlman destroyed electronic evidence of his falsifications and fabrications, presented false testimony, presented falsified documents, and influenced other witnesses to provide false documents to the investigating authorities. In September 2001, Dr. Poehlman resigned from UVM and moved to Montreal, Canada to work as an academic researcher. Dr. Poehlman has subsequently left his academic position in Canada.
Following the UVM investigation, the matter was referred to the United States Attorney's Office and the ORI within the Public Health Service. Scientists at ORI working with investigators at OIG-HHS and the United States Attorney's Office then conducted a far-reaching investigation into all of Dr. Poehlman's grant applications and scientific publications. As a result of this investigation, Dr. Poehlman agreed to enter into the comprehensive criminal, civil, and administrative settlement filed in U.S. District Court today.
The United States Attorney's Office wishes to recognize the hard work and dedication of UVM professors and staff who conducted the initial investigation of Dr. Poehlman's scientific misconduct. A redacted version of the UVM Investigative Report is included in the court documents filed today. As part of the agreements filed today, Dr. Poehlman has accepted the findings in the UVM Investigative Report.
ORI and the U.S. Attorney's Office also acknowledge the important role that individual scientists have in identifying and responding to research misconduct. ORI depends largely on the assistance of honest research scientists in the lab in discovering and reporting suspected misconduct, as occurred in this case. Without their assistance, ORI and HHS would have great difficulty in taking appropriate actions to protect the public health.
The United States Attorney's Office also wishes to recognize the professionalism and tireless efforts of the scientific and criminal investigators at the ORI and the OIG, and the attorneys in the Office of General Counsel at HHS.
Dr. Poehlman is represented by Robert B. Hemley, Esq., and Andrew D. Manitsky, Esq., of Gravel and Shea in Burlington, Vermont. The criminal and civil cases are being handled by Assistant U.S. Attorneys Carol L. Shea and Stephen D. Kelly.
|